Tuesday, 30 August, 2016
Ben Warner
,
Emma Johnston
,
Monica Arenas-Hernandez
,
,
Peter Irving
,
Jeremy Sanderson
Tuesday, 12 July, 2016
Pavlidis P
,
Gulati S
,
Dubois P
,
Chung Faye G
,
,
Hayee B
Tuesday, 30 June, 2015
The development of infliximab (IFX) drug level and anti-drug antibody (ADA) testing has allowed a personalised approach to IFX use in inflammatory bowel disease (IBD). We present our 2-year experience at a tertiary IBD centre.
EL Johnston
,
BD Warner
,
JL Digby-Bell
,
Nick Unsworth
,
S Anderson
,
JD Sanderson
,
,
PM Irving
Tuesday, 30 June, 2015
Commercial assays are now available for therapeutic drug monitoring (TDM) of anti-TNF drugs and antibodies (ADAb). Utility of free versus total ADAb assays remains debatable, further complicated by lack of assay standardisation. Here we report analytical comparison of 3 commercially available assays for Infliximab (IFX) and Adalimumab (ADAL) drug levels (DL) and ADAb.
,
Nick Unsworth
,
BD Warner
,
Gill Richards
,
PM Irving
Tuesday, 30 June, 2015
Therapeutic drug monitoring (TDM) of Infliximab (IFX) and Adalimumab (ADAL) has been in use in our centre since 2012. Here we present the TDM experience of our laboratory service at Viapath, St Thomas’ Hospital.
,
Nick Unsworth
,
Gill Richards
,
Zain Odho
,
PM Irving
Tuesday, 30 June, 2015
The development of adalimumab (Ada) drug and antibody testing has allowed a personalised approach to complex inflammatory bowel disease (IBD) treatment. We present our 2-year experience at a tertiary IBD referral centre.
BD Warner
,
EL Johnston
,
JL Digby-Bell
,
Nick Unsworth
,
S Anderson
,
JD Sanderson
,
,
PM Irving
Tuesday, 30 June, 2015
Clinical trial results suggest that measurement of antiTNF drug levels (ATL) and antibodies (ATA) may have a cost-saving as well as clinically beneficial effect in patients with IBD. We aimed to assess whether selective monitoring of ATL and ATA reduces prescribing costs and how it affects clinical decisions in ordinary clinical practice.
TA Tandiari
,
A Ibarra
,
L Younge
,
A Palma Allepuz
,
A Thompson
,
U Meade
,
,
E Giles
,
L Langmead
,
JO Lindsay
,
G Parkes
,
D Rampton
Monday, 8 June, 2015
Therapeutic drug monitoring (TDM) of Infliximab (IFX) has been in use in our centre since 2012 and has become increasingly widespread in the UK with the availability of several CE marked assays. TDM of IFX is useful in optimisation of therapy in patients with inflammatory bowel disease (IBD). The detection of antibodies against Infliximab can guide clinical decision making with regard to dose escalation, immunomodulation or drug switching / withdrawal. However the utility of measuring free
versus total (IFX-complex + free) anti-Infliximab antibody (ADAb) remains debatable, further complicated by lack of assay standardisation.
Nick Unsworth
,
MG Ward
,
PM Irving
,
BD Warner
,
Wednesday, 25 February, 2015
Therapeutic drug monitoring (TDM) of infliximab (IFX) is useful in patients with inflammatory bowel disease (IBD). Therapeutic cut-offs to predict active disease and the influence of thiopurines on drug levels (DL) according to 6-thioguanine nucleotide (TGN) are not defined. There is limited data on the utility of free anti-drug antibodies (ADAb) against total ADAb. We assessed the utility of TDM of IFX in IBD using a commercially available ELISA and investigated the influence of TGNs on DL and free/total ADAb.
M Ward
,
B Warner
,
Nick Unsworth
,
J Sanderson
,
,
P Irving
Wednesday, 25 February, 2015
Some, but not all, studies have demonstrated a relationship between therapeutic drug monitoring (TDM) of adalimumab (ADA) and outcomes in Crohn's disease (CD). We evaluated the utility of TDM of ADA in patients with CD using two commercially-available ELISA.
M Ward
,
B Warner
,
SW Chuah
,
S Shieh
,
Nick Unsworth
,
J Sanderson
,
M Parkes
,
,
P Irving
Monday, 28 October, 2013
MG Ward
,
VC Kariyawasam
,
SB Mogan
,
PA Blaker
,
KP Patel
,
M Pantelidou
,
S Anderson
,
JD Sanderson
,
Nick Unsworth
,
,
PM Irving
Tuesday, 13 August, 2013
A substantial proportion of patients with psoriasis do not respond or lose initial response to tumour necrosis factor antagonists.
S.K. Mahil
,
,
G. Richards
,
C.M. Lewis
,
J.N. Barker
,
C.H. Smith
Thursday, 27 June, 2013
Commercial assays for monitoring Infliximab (IFX) and anti-drug antibodies (ADAb) are currently available.
Nick Unsworth
,
,
P. Irving
,
M.G.Ward
,
G. Richards
Friday, 14 June, 2013
Up to 1/5 of patients with wildtype thiopurine-S-methyltransferase (TPMT) activity prescribed azathioprine (AZA) or mercaptopurine (MP) demonstrate a skewed drug metabolism in which MP is preferentially methylated to yield methylmercaptopurine (MeMP)
Blaker PA
,
Arenas-Hernandez M
,
Smith MA
,
Shobowale-Bakre EA
,
Fairbanks L
,
Irving PM
,
Sanderson JD
,
Marinaki AM
Tuesday, 4 June, 2013
Br J Cancer. 2013 Jun 25;108(12):2505-15. doi: 10.1038/bjc.2013.262. Epub 2013 Jun 4.
Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM
Tuesday, 4 June, 2013
Fluoropyrimidine drugs are extensively used for the treatment of solid cancers.
Loganayagam A,
,
Arenas-Hernandez M
,
Corrigan A
,
L Fairbanks
,
Lewis CM
,
Harper P
,
Maisey N
,
Ross P
,
Sanderson JD
,
Marinaki AM
Tuesday, 30 April, 2013
Pre-treatment measurement of red blood cell (RBC) thiopurine-S-methyltransferase (TPMT) activity is recommended to guide initial dosing of azathioprine (AZA) and mercaptopurine (MP).
P A Blaker
,
V C Kariyawasam
,
K V Patel
,
R M Goel
,
M G Ward
,
P M Irving
,
,
J D Sanderson
Thursday, 18 April, 2013
NICE guidance recommends the use of biologic drugs for the treatment of inflammatory disease in Rheumatology, Dermatology and Gastroenterology with restrictions.
,
N Unsworth
,
G Richards
,
P Irving
,
M Ward
Wednesday, 27 February, 2013
A substantial proportion of patients with psoriasis do not respond or lose initial response to tumour necrosis factor antagonists.
Dr SK Mahil
,
,
G Richards
,
JN Barker
,
CH Smith
Monday, 17 December, 2012
Int J Clin Pract. 2013 Feb;67(2):161-9. doi: 10.1111/ijcp.12039. Epub 2012 Dec 17.
Smith M, Blaker P, Patel C, Marinaki A, Arenas M, Escuredo E, Anderson S, Irving P, Sanderson J
Monday, 9 July, 2012
Woolf RT, West SL, Arenas-Hernandez M, Hare N, Peters van Ton AM, Lewis CM, Marinaki AM, Barker JN, Smith CH.
